ArticleScientific reports2026
Detection of heteroresistance in Mycobacterium tuberculosis using nanopore-based amplicon sequencing and adaptive sampling.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Heteroresistance (HR) in Mycobacterium tuberculosis-the coexistence of drug-susceptible and drug-resistant subpopulations within the same host-poses a major obstacle to effective tuberculosis (TB) diagnosis, treatment, and control. The primary objective of this study was to determine whether Oxford Nanopore Technologies (ONT)-based workflows could accurately detect heteroresistance and compare their performance. To achieve this, we first optimized ONT sequencing workflows using cultured isolates and TB-positive clinical sputum, identifying phenol-based DNA extraction with ligation library as the best-performing combination, though Kit-Ligation had the best performance in amplicon sequencing from culture. We then evaluated two enrichment strategies-amplicon sequencing and Adaptive sampling (AS)-using synthetic mixtures of drug-susceptible (H37Rv) and drug-resistant (DM97) strains at defined ratios. Amplicon sequencing achieved coverage > 4,000× across target genes and reliably detected resistant alleles at frequencies as low as 1%. AS enriched 14 resistance loci with ~ 3-fold higher on-target depth compared to non-enriched nanopore whole-genome sequencing (WGS), enabling accurate detection of resistant subpopulations at 5% while retaining genomic context for lineage assignment. Together, these results demonstrate that, among the ONT workflows evaluated, nanopore amplicon sequencing provides superior sensitivity, whereas AS offers an intermediate approach, increasing depth while retaining some genomic context. These complementary approaches represent scalable strategies that could enhance TB heteroresistance detection and surveillance in high-burden settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.